Background. This randomized, open trial compared regimens including 2 doses (2D) of human
papillomavirus (HPV) 16/18 AS04-adjuvanted vaccine in girls aged 9–14 years with one …

Background. We previously reported the noninferiority 1 month after the last dose of 2-dose
human papillomavirus 16/18 AS04-adjuvanted (AS04-HPV-16/18) vaccine schedules at …

… the study (148 in the vaccine group, 146 in placebo group). All … vaccine group had
seroconverted for human papillomavirus–… which human papillomavirus types shall we vaccinate …

… The vaccine was well tolerated with no increase in reactogenicity with subsequent doses …
no reports of vaccine-related SAEs. In conclusion, the HPV-16/18 AS04-adjuvanted vaccine is …

… data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme…
safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 …

… human papillomavirus (HPV)-16 and -18 accounts for over 70% of all cases of cervical
cancer. Vaccination … ), an AS04-adjuvanted HPV-16/18 vaccine, and considers immunological …

… adjuvanted vaccine targeting human papillomavirus types 16 and 18 (AS04-HPV-16/18)
vaccine … or higher irrespective of type, among women vaccinated before sexual debut. This high …

… safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in …
trial with two parallel groups, the Vaccine and Placebo groups, included 354 subjects in four …

… aluminum hydroxide (together called adjuvant system 04, AS04) as an adjuvant [32]. MPL
is … contain only aluminum hydroxide as an adjuvant and are produced in Saccharomyces …

… -16/18 AS04-adjuvanted vaccine has demonstrated to be highly … which human papillomavirus
types shall we vaccinate and … Human papillomavirus type distribution in invasive cervical …